Long Bow expandable lateral interbody system receives FDA approval

937

Life Spine has announced today that the FDA has given 510(k) marketing clearance for its Long Bow expandable lateral interbody system. A press release reports that the system is the first interbody on the market that expands laterally in-situ specifically for a direct lateral approach.

According to the press release, the Long Bow is scheduled for limited release at the end of 2014 with full product release expected in the first quarter of 2015.


“With the Long Bow interbody system, surgeons can decrease the amount of retraction by as much as 45% compared to current lateral systems. The benefits of the system are transferred directly to the patient by minimising tissue retraction and potential nerve damage associated with the lateral access approach,” says Richard Greiber, Vice president of business development and professional relations.